Related Experiment Video
Updated: Feb 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
Zhonglin Cai1, Weijie Chen2, Jianzhong Zhang1
1Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Abstract:
Androgen deprivation therapy is an important therapy for prostate cancer (PCa) in aging men. Under the background of castration, it is inevitable that prostate cancer will develop into castration-resistant prostate cancer (CRPC), which has a high mortality rate, after 2-3 years. Androgen receptor (AR) plays a key role in PCa development and is essential to CRPC. More recent research studies have reported that the development of CRPC is largely due to altered mechanisms related to AR, so it is important for us to understand the roles of AR and detailed AR-related mechanisms in CRPC. The multiple AR-related mechanisms promoting the development of CRPC are as follows: (1) enhanced transformation and increased synthesis of intratumoral androgen; (2) AR overexpression, which enables CRPC to be hypersensitive to low levels of androgen; (3) AR cofactors, which enhanced AR transactivation; (4) AR-spliced variants, which mediated downstream gene expression without androgen; (5) the interaction between the AR pathway and classic tumor-related pathways; and» (6) AR mutations, which reduced AR specificity and enhanced AR transcription.
Insights
Prostate cancer (PCa) often becomes castration-resistant prostate cancer (CRPC) despite androgen deprivation therapy. Understanding androgen receptor (AR) alterations is key to combating CRPC progression.
Area of Science:
- Oncology
- Urology
- Molecular Biology
Background:
- Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer (PCa).
- Prostate cancer frequently progresses to castration-resistant prostate cancer (CRPC) within 2-3 years of ADT.
- The androgen receptor (AR) pathway is critical in PCa and remains essential for CRPC development.
Purpose of the Study:
- To elucidate the multifaceted AR-related mechanisms driving CRPC development.
- To highlight the importance of understanding AR's role in CRPC progression.
Main Methods:
- Review and synthesis of current research on AR signaling in CRPC.
- Analysis of specific AR-related mechanisms contributing to treatment resistance.
Main Results:
- CRPC development is linked to altered AR mechanisms.
- Key mechanisms include increased intratumoral androgen synthesis, AR overexpression, enhanced AR cofactors, AR-spliced variants, AR pathway interactions with other tumor pathways, and AR mutations.
Conclusions:
- Understanding AR-related mechanisms is crucial for developing effective CRPC treatments.
- Targeting these AR alterations may offer new therapeutic strategies for castration-resistant prostate cancer.
Related Concept Videos
Expected Value
Internal Receptors
Treatment Resistant Cancers
Determination of Expected Frequency
Resistivity
Resistance

